In patients with refractory lymphoma, we tested the hypothesis that high-dose chemotherapy (BEAM) without stem cell support followed by a reduced intensity (RIC) allogeneic transplant with fludarabine and 2 Gy TBI 28 days later results in tumor debulking and establishment of a graft vs lymphoma effect, with acceptable toxicity. In a pilot protocol we treated 10 patients, 22-62 (median 47) years of age with high-risk or refractory Hodgkin's or non-Hodgkin's lymphoma. Donors were HLA identical siblings (eight) or unrelated volunteers. None died during the neutropenic phase after BEAM which lasted up to the RIC HSCT. The duration of neutropenia was 31-43 (median 36) days. All patients engrafted and nine achieved CR. All developed acute GvHD (median grade III) and all patients at risk developed chronic GvHD. Three patients died of GvHD. One relapsed and six patients are in continuous CR 10-32 (median 15) months after HSCT. This approach appears feasible and results in a high response rate. Neutropenia duration is of concern. It remains to be tested whether separation of debulking chemotherapy and induction of allogeneic effects confers an advantage.
intensity allogeneic stem cell transplantation Hematopoetic stem cell transplantation (HSCT) is not generally considered as first-line therapy for patients with lymphoid neoplasia. Its place is seen to be in advanced or relapsing disease, and autologous HSCT is the preferred choice. Autologous HSCT is an established therapy in patients with chemosensitive relapse. 1 Prospective controlled study data document a survival advantage compared to conventional chemotherapy, but relapse remains of concern.
2 Little benefit is derived from autologous HSCT for advanced or chemotherapy refractory disease. Alternative approaches are warranted.
Allogeneic HSCT constitutes less than 10% of all HSCT in lymphoma. 3 There is clear evidence of a graft-vslymphoma (GvL) effect, 4, 5 However, toxicity is substantial and transplant-related mortality is high. 6 Despite improved disease control, there is no documented survival benefit for allogeneic HSCT. 7, 8 New strategies include reduced intensity conditioning (RIC) allogeneic HSCT. 9 GvL is said to be the same as in standard conditioning, with less toxicity. Initial data are promising but again restricted to responsive disease. In refractory or relapsed disease, or in patients with a high tumor load, response is unsatisfactory. It appears that GvL requires time to be effective. Tumor control at the time of RIC HSCT appears to be essential. Carella and co-workers 10 were the first to make use of a novel strategy and to combine high-dose chemotherapy and autologous HSCT followed by RIC allogeneic HSCT. Separation of tumor debulking and allogeneic GvL effect is supposed to limit toxicity while preserving GvL effects. Initial data were promising but remained uncomfirmed, in part because in many patients with refractory or relapsing lymphoma peripheral stem cells cannot be mobilized. In addition, despite purging strategies, reinfusion of tumor cells remains of concern. 11 We assumed that by using high-dose chemotherapy with BEAM we could achieve tumor debulking in high-risk lymphoma patients. We hypothesized that without stem cell support, patients would be severely neutropenic but with minimal tumor burden and reduced host antigen presenting cells. We postulated that by adding a RIC allogeneic transplant 4 weeks after BEAM chemotherapy, we could induce GvL without severe GvHD and that toxicity would be acceptable. The chemotherapy-associated cytokine storm should be over at the time of the allogeneic transplant and no longer be able to trigger GvHD. The purpose of this pilot study was to assess feasibility and efficacy of such sequential administration of high-dose chemotherapy without stem cell support, followed by allogeneic low intensity conditioning peripheral stem cell transplantation in patients with lymphoproliferative disorders refractory to standard treatment or very high risk disease.
Patients and methods

Study design
This was a prospective single center phase I/II feasibility study. A predetermined number of 10 patients with refractory, relapsing or high-risk lymphoid malignancy were to be enrolled. The protocol was to be stopped in the event of three consecutive treatment-related deaths. Informed consent was obtained from patients and donors. Outcomes analyzed included toxicity of the BEAM phase, number of days in aplasia, incidence and speed of donortype engraftment, incidence and severity of GvHD, tumor response, progression-free survival and survival.
Patients
The 10 patients were between 22 and 62 years of age, seven were male and three female as outlined in Table 1 . They all had lymphoid malignancies and had failed a median of five (1-7) lines of treatment, including autologous HSCT in one. All but the two patients with HD had failed rituximab. Patients were considered high risk because of transformed follicular lymphoma (two) or transformed CLL (one), blastic phase mantle cell lymphoma (one), failed autologous transplant (one), failed multiple treatments (five).
Donors were HLA identical siblings in eight patients, and unrelated donors (12/12 matches and 11/12 matches) in two patients.
Treatment regimen
The treatment regimen consisted of high-dose chemotherapy with BEAM (Etoposide 200 mg/m 2 twice daily i.v. for 4 consecutive days (total eight doses), BiCNu (carmustine) 300 mg/m 2 one dose i.v. at day 1, Ara-C 200 mg/m 2 twice daily i.v. for 4 consecutive days (total eight doses), melphalan 140 mg/m 2 once i.v. at day 5. This was followed by allogeneic reduced intensity conditioning peripheral stem cell transplantation on day þ 28 of BEAM using fludarabine 30 mg/m 2 on 3 consecutive days i.v. and 2 Gy TBI for conditioning. Cyclosporine and mycophenolate mofetil were used for GvHD prophylaxis as described by the Seattle group. 12 
Results
Feasibility
All patients were treated according to plan. BEAM chemotherapy was tolerated with its usual toxicities. No fatal event occurred during this treatment phase. Nonhematological toxicity was defined according to the WHO criteria. The day of maximum toxicity was day 15 (14-26) after BEAM, with infection (median grade 2; range 1-3) and mucositis (median grade 3; range 2-4) being present in all patients.
All 10 patients proceeded to the planned reduced intensity conditioning HSCT at the planned day 28 (median, range 25-32 days). All were neutropenic (as defined as having an ANC below 0.5 Â 10 up to day 11.5 (9-18) after HSCT. The total time of neutropenia was 36 (31-43) days. All patients achieved engraftment (defined as reaching 0.5 Â 10 9 /l neutrophils stable over three days) at a median of 11.5 (9-18) days. All patients recieved i.v. antibiotics for 60 days (median, range 34-140 days) and i.v. antifungals for 35 days (median, range 2-98 days). In all, 11 platelet (median, range 8-88 ) and eight red blood cell transfusions (median, range 6-70 ) were needed as supportive measures.
Efficacy
One patient was in CR at the time of treatment. He remained in CR. Eight of nine patients who were refractory prior to treatment entered complete remission as best response. Persistent disease was observed in one patient with refractory advanced CLL ( Table 2 ).
Post-transplant complications
All patients developed acute GvHD with a median grade III (I-IV). All eligible patients (7/7) developed chronic GvHD, two limited and five extensive.
Infectious complications after allogeneic HSCT were frequent, especially fungal complications. There were three proven and one probable invasive pulmonary aspergillosis according to EORTC criteria. 13 
Survival
At the last follow-up (median 15 months; range 10-32), six patients were alive and well with no evidence of disease. One patient had relapsed 11 months after transplantation and three had died. Of those surviving, two are off systemic immunosuppression and four are still being treated for GvHD. The cause of death was GvHD in remission in one patient, GvHD and septicemia in one patient, and progressive CLL despite GvHD.
Discussion
High-dose chemotherapy using BEAM without autologous stem cell support followed by allogeneic RIC transplantation is feasible. Toxicity is considerable, but in our study no fatal toxic events occurred during aplasia. Patients were treated as planned and allogeneic transplantation was performed on time, on day 28, in all. Patients were severely pancytopenic at the time of allogeneic RIC transplantation, but all had recovered from mucositis at that time. Transfusional support was substantial and infectious complications occurred in every patient, requiring i.v. antibiotic treatment.
We observed high rates of acute GvHD. Three of 10 patients died with acute GvHD, which seems not to be a rate lower than expected with myeloablative allogeneic transplantation. We had hypothesized that GvHD would be less than with myeloablative allogeneic HSCT due to two mechanisms. (1) separating high-dose chemotherapy from the allogeneic effect may downregulate GvHD by avoiding exposure of allogeneic T-cells to cytokines and /l) at the time of RIC transplantation but tissue antigen presenting cells were not measured. The observed frequency and severity of GvHD does not favor our hypothesis and does not point towards a substantial reduction of GvHD risks with this regimen.
Given the high-risk status of these patients, tumor response is satisfactory. The best response was complete remission in nine of 10 patients, and some of these patients have become long-term responders in spite of having failed multiple treatments. The median follow-up of 15 months is short, however. Tumor debulking using high-dose chemotherapy and an autologous HSCT followed by allogeneic RIC HSCT has been postulated as a concept and is used frequently today, especially for myeloma patients. 14, 15 No prospective studies have proven the superiority of such an approach. Infusion of autologous stem cells shortens aplasia duration, but puts the patient at risk of reinfusion of tumor cells. Here, we show that in patients where no stem cells can be harvested, use of HDC followed by RIC allogeneic HSCT is feasible. This is a small study with a limited number of patients. This protocol of high-dose chemotherapy using BEAM without autologous transplantation followed by RIC allogeneic HSCT achieved a high rate of complete remission, albeit at the cost of considerable toxicity. Duration of neutropenia remains a problem and GvHD appears not to be reduced. The potential benefit of separating high-dose chemotherapy and RIC by time needs to be studied further in patients with lymphoma.
